Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced the pricing of its previously announced underwritten public offering of 5 million shares of common stock at $20.00 per share, generating expected gross proceeds of approximately $100 million. The company has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to customary closing conditions.
Nuvectis stated that it intends to use the net proceeds to advance development of its NXP100, NXP200, and NXP900 programs, support future product candidates, hire additional personnel, fund capital expenditures, and cover general corporate purposes. Cantor is serving as sole book-running manager, with H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners acting as co-managers.
Nuvectis Pharma is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The company’s pipeline includes NXP100, a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers. NXP100 is a late-stage Factor B inhibitor with best-in-class potential as an effective therapy in multiple complement-mediated diseases, offering a convenience advantage as the only once-daily oral treatment option for these diseases requiring life-long treatment. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, intended to inhibit the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP200 is an oral, brain penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, including central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer, with best-in-class potential.
The $100 million capital raise is significant for Nuvectis as it provides the financial resources to advance its pipeline through clinical development. The proceeds will support the progression of NXP100, which targets complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria and other conditions where complement dysregulation plays a role. The once-daily oral formulation could offer a significant advantage over existing injectable therapies, potentially improving patient compliance and quality of life.
In oncology, NXP900 and NXP200 address areas of high unmet need. NXP900’s dual inhibition of catalytic and scaffolding functions of SRC kinase may provide a broader antitumor effect, while NXP200’s brain penetrant properties could make it a valuable option for BRAF-mutated central nervous system tumors, a challenging area where current therapies have limited efficacy. The funding will also allow Nuvectis to expand its team and infrastructure, which are critical for conducting clinical trials and regulatory submissions.
The involvement of multiple underwriters, including Cantor and H.C. Wainwright, reflects strong institutional interest in Nuvectis’s pipeline. The successful pricing at $20 per share indicates investor confidence in the company’s strategy and the potential of its drug candidates. The additional 30-day option for up to 750,000 shares provides flexibility to raise further capital if demand warrants.
For more information, visit https://nuvectis.com/.
